GeoVax Labs (NASDAQ:GOVX – Get Free Report) had its target price increased by equities research analysts at HC Wainwright from $8.00 to $120.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock.
GeoVax Labs Trading Up 71.2 %
NASDAQ GOVX opened at $1.90 on Tuesday. The stock has a 50-day simple moving average of $1.62 and a two-hundred day simple moving average of $2.87. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $10.24.
GeoVax Labs (NASDAQ:GOVX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter.
Institutional Trading of GeoVax Labs
GeoVax Labs Company Profile
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
Featured Articles
- Five stocks we like better than GeoVax Labs
- Where to Find Earnings Call Transcripts
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Trading Stocks: RSI and Why it’s Useful
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- How to Capture the Benefits of Dividend Increases
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.